Method for applying electrochemical destruction, surgical removal and photodynamic prophylaxis for treating the cases of intraocular neoplasms in perfluororganic medium

FIELD: medicine.

SUBSTANCE: method involves filling vitreous cavity with perfluororganic compound. Two electrodes manufactured from platinum group metal are intravitreally, transretinally introduced into intraocular neoplasm. Electrochemical destruction is carried out with current intensity of 10-100 mA during 1-10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2 in perfluororganic compound medium. The transformed retina and tumor destruction products are intravitreally removed with perfluororganic compound volume being compensated with its additional introduction. Boundary-making endolasercoagulation of retinotomy area is carried out. The perfluororganic compound is substituted with silicon oil. The operation is ended in placing sutures over sclerotmy areas and over conjunctiva. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity. Platinum, iridium or rhodium are used as the platinum group metals.

EFFECT: complete destruction of neoplasm; reduced dissemination risk.

6 cl, 12 dwg

 

The invention relates to medicine, namely to ophthalmology, to methods of electrochemical degradation, surgical resection and photodynamic relapse prevention of intraocular tumors in the environment performancesthe connection with their Central location.

There is a method of surgical treatment and surgical removal of tumors, including performing a vitrectomy, a surgical removal of intraocular tumors and silicone oil tamponade (see Jose Garsia-Arumi, MD, Laura Sararols, MD, Vincent Martinez, MD, Borja Cjrcjstegui, MD, "Vitreoretinal Surgery and endoresection in high posterior choroidal melanomas, RETINA, 21:445-452, No. 5, 2001).

However, the known method when its use does not allow the deletion in full (within healthy tissue) intraocular tumors, remission of tumor cells in the surgical field, does not preclude the dissemination of tumor cells and metastasis.

The basis of the invention is to provide a method of electrochemical degradation, surgical resection and photodynamic relapse prevention of intraocular tumors in the environment performancesthe connection, allowing for its use to achieve the total destruction of intraocular tumors, exceptions separation of tumor cells in the surgical field, reducing ri is the ka of tumour cell dissemination and metastasis.

The problem is solved in that a method of electrochemical degradation, surgical resection and photodynamic relapse prevention of intraocular tumors in the environment performancesthe connection, comprising performing a vitrectomy, a surgical removal of intraocular tumors and tamponade with silicone oil, the distinguishing feature of which is that after vitrectomy fill vitreal cavity performancesin connection intravitreal, transnationale in intraocular neoplasm introduce two electrodes made of platinum group metal, carried out the electrochemical degradation of intraocular tumors with amperage 10-100 mA within 1-10 minutes when changing the polarity of the electrodes and their location on the volume of intraocular tumors, remove the electrodes, then intravenous enter as a photosensitizer 0.1 to 1% aqueous solution of chlorine selected from the group Photolon, Radachlorin or photoditazine at a dose of 0.8-1.1 mg/kg, carry out a visual inspection of the fluorescence of the cells of intraocular tumors using fluorescent diagnostics, and upon reaching the maximum level of saturation of intraocular tumors photosensitizer spend it intravitreal, TRANSRATE the social environment performancesthe connection laser irradiation parallel light beam with a wavelength of 661-666 nm within 60-180 seconds for a total dose of irradiation 30-120 j/cm 2then using vitrectomy intravitreal remove modified the retina and the products of destruction of tumor tissue-compensated volume performancesthe connection additional introduction, conduct the restrictive endolasercoagulation section retinotomy replace performancesee connection with silicone oil, and the surgery is completed by suturing the areas of sclerotome and conjunctiva. At the same time as performancesthe connection to fill the vitreal cavity using, for example, performancecriteria, performability or parfocality. As a platinum group metal electrodes using platinum, iridium or rhodium.

In the clinical practice of using the proposed method, electrochemical destruction, surgical resection and photodynamic relapse prevention of intraocular tumors in the environment performancesthe connection has been established with the use of all the selected parameters of the proposed method achieved the following technical result: the total destruction of intraocular tumors with the exception of leaving tumor cells in the surgical field, reduced the risk of tumour cell dissemination and metastasis.

For illustrate the proposed method on the drawings schematically shows his main stages (option 1).

Implementation of the proposed method is illustrated by the following clinical examples.

Example 1. Patient M., 56 years old, was admitted to the Kaluga branch of IRTC “eye microsurgery” with suspected tumors of the choroid right eye.

When the survey was diagnosed with melanoma of the choroid OD. Localization of lesions in the posterior pole of the eye. The size of the tumor by ultrasound B-scan: 10 to 12 mm, the size of prominence to 5 mm During PHAGE was detected characteristic "spotted" fluorescence in tumors.

Previously spent clarifying the true boundaries of the tumor by the method of transillumination.

At the preparatory stage after processing operating margins held anesthetic management. Spent vitrectomy and filled the vitreal cavity performability. Then intravitreal, transnationale in intraocular neoplasm introduced two electrode made of iridium, and spent the electrochemical degradation of intraocular tumors with rated current of 10 mA for 10 minutes when changing the polarity of the electrodes and their location on the volume of intraocular tumors. The electrodes were removed and intravenous introduced as a photosensitizer 1% aqueous solution of chlorine, namely photodithazine, the dose of 0.8 mg/kg Then made a visual inspection of fluorescence of cells intraocular tumors using fluorescent diagnostics, and upon reaching the maximum level of saturation of intraocular tumors photosensitizer spent his intravitreal, transnationale environment performability laser irradiation parallel light beam with a wavelength of 661 nm for 180 sec with a total dose of 120 j/cm2. Using vitrectomy intravitreal deleted modified the retina and the products of destruction of tumor tissue, was compensated volume performability additional introduction, spent restrictive endolaser coagulation section retinotomy. Performability was replaced with a silicone oil, and the operation is finished suturing the areas of sclerotome and conjunctiva.

When the control ULTRASOUND after 6 months on the location of the mass was determined by dense scar up to 1 mm thick. Installed total destruction of intraocular tumors, excluded the remission of tumor cells in the surgical field, reduced the risk of tumour cell dissemination and metastasis.

Example 2. Patient R., 67 years old, was admitted to the Kaluga branch of IRTC “eye microsurgery” with suspected tumors of the choroid lion is th eye.

When the survey was diagnosed with melanoma of the choroid OS. Localization of lesions in the posterior pole of the eye. The size of the tumor by ultrasound B-scan: 9 to 11 mm, the size of prominence - up to 5 mm During PHAGE was detected characteristic "spotted" fluorescence in tumors.

Previously spent clarifying the true boundaries of the tumor by the method of transillumination.

At the preparatory stage after processing operating margins held anesthetic management. Spent vitrectomy and filled the vitreal cavity performancecriteria. Then intravitreal, transnationale in intraocular neoplasm introduced two electrodes made of platinum, and spent the electrochemical degradation of intraocular tumors with rated current 100 mA for 1 minute when the polarity of the electrodes and their location on the volume of intraocular tumors. The electrodes were removed and intravenous introduced as a photosensitizer 0.1% aqueous solution of chlorine, namely, Photolon dose of 1.1 mg/kg Then carried out a visual inspection of fluorescence of cells intraocular tumors using fluorescent diagnostics and upon reaching the maximum level of saturation of intraocular tumors photosensible what Isadora spent his intravitreal, transretinol environment performancecriteria laser irradiation parallel light beam with a wavelength of 666 nm for 60 sec. with a total dose of 30 j/cm2. Using vitrectomy intravitreal deleted modified the retina and the products of destruction of tumor tissue, was compensated volume performancecriteria additional introduction, spent restrictive endolaser coagulation section retinotomy. Performancecriteria was replaced with a silicone oil, and the operation is finished suturing the areas of sclerotome and conjunctiva.

When the control ULTRASOUND after 6 months on the location of the mass was determined by dense scar up to 1 mm thick. Installed total destruction of intraocular tumors, excluded the remission of tumor cells in the surgical field, reduced the risk of tumour cell dissemination and metastasis.

The invention relates to medicine, namely to ophthalmology, to methods of electrochemical degradation, surgical resection and photodynamic relapse prevention of intraocular tumors in the environment performancesthe connection with their peripheral localization.

There is a method of surgical treatment and surgical removal of tumors, VK is uchumi performing vitrectomy, surgical removal of intraocular tumors and silicone oil tamponade (see Jose Garsia-Arumi, MD, Laura Sararols, MD, Vincent Martinez, MD, Borja Cjrcjstegui, MD, "Vitreoretinal Surgery and endoresection in high posterior choroidal melanomas, RETINA, 21:445-452, No. 5, 2001).

However, the known method when its use does not allow the deletion in full (within healthy tissue) intraocular tumors, remission of tumor cells in the surgical field, does not preclude the dissemination of tumor cells and metastasis.

The basis of the invention is to provide a method of electrochemical degradation, surgical resection and photodynamic relapse prevention of intraocular tumors in the environment performancesthe connection, allowing for its use to achieve the total destruction of intraocular tumors, exceptions separation of tumor cells in the surgical field, reducing the risk of tumour cell dissemination and metastasis.

The problem is solved in that a method of electrochemical degradation, surgical resection and photodynamic relapse prevention of intraocular tumors in the environment performancesthe connection, comprising performing a vitrectomy, a surgical removal of intraocular tumors and tamponade with silicone oil is m, the distinctive feature of which is that after vitrectomy vitreal cavity fill performancesin connection transscleral diaphanoscopy precise localization and dimensions of intraocular neoplasms, then 2/3 of the thickness of the sclera above the intraocular neoplasm form a scleral pocket rectangular base from limb, formed through the bed is introduced into the structure of intraocular neoplasms multiple electrodes made of platinum group metal, changing the polarity of conduct electrochemical destruction of intraocular tumors with amperage 10-100 mA for 1-10 minutes and remove the electrodes, the superficial scleral flap returns to its place and fixed with interrupted sutures, is injected as a photosensitizer 0,1-1% aqueous solution of chlorine selected from the group Photolon, Radachlorin or photoditazine, at a dose of 0.8-1.1 mg/kg, then carry out a visual inspection of the fluorescence of the cells of intraocular tumors using fluorescent diagnostics, and upon reaching the maximum level of saturation of intraocular tumors photosensitizer spend it intravitreal, transnationale environment performancesthe connection laser irradiation parallel beam of light from donovani 661-666 nm within 60-180 sec with a total dose of 30 to 90 j/cm 2then using vitrectomy intravitreal remove modified the retina and the products of destruction of tumor tissue-compensated volume performancesthe connection additional introduction, conduct the restrictive endolasercoagulation section retinotomy replace performancesee connection with silicone oil, and the surgery is completed by suturing the areas of sclerotome and conjunctiva. At the same time as performancesthe connection to fill the vitreal cavity using, for example, performancecriteria, performability or parfocality. As a platinum group metal electrodes using platinum, iridium or rhodium, and the number of electrodes selected from 4 to 8.

In the clinical practice of using the proposed method, electrochemical destruction, surgical resection and photodynamic relapse prevention of intraocular tumors in the environment performancesthe connection has been established with the use of all the selected parameters of the proposed method obtained the following technical result: achieved total destruction of intraocular tumors, excluded the remission of tumor cells in the surgical field, reduced the risk of tumour cell dissemination. About Westley prevention of metastasis.

To illustrate the proposed method on the drawings schematically shows his main stages (option 2).

Implementation of the proposed method is illustrated by the following clinical examples.

Example 1. Patient I., 56 years old, was admitted to the Kaluga branch of IRTC “eye microsurgery” diagnosis “melanoma of the choroid of the right eye”. Localization of tumor - postequalization in the lower outer quadrant. The size of the tumor according to the ULTRASONIC B-scanning: 6 to 8 mm and a height of prominence 4 mm.

At the preparatory stage after processing processing operating margins held anesthetic management. Then had a vitrectomy and filled the vitreal cavity piptochaetium. Transscleral diaphanoscopy said localization and dimensions of intraocular tumors. Then 2/3 of the thickness of the sclera above the intraocular neoplasm formed scleral pocket rectangular base from the limbus. Through the formed bed introduced into the structure of intraocular tumors 4 electrode made of iridium. Spent the electrochemical degradation of intraocular tumors with rated current of 10 mA for 10 minutes and removed the electrodes. The superficial scleral flap was returned to its place and recorded interrupted sutures. Then intravenously introduced as f is of desensibilization 1% aqueous solution of chlorine, namely Photolon, at a dose of 0.8 mg/kg Conducted a visual inspection of fluorescence of cells intraocular tumors using fluorescent diagnostics, and upon reaching the maximum level of saturation of intraocular tumors photosensitizer spent his intravitreal, transnationale environment parfocality laser irradiation parallel light beam with a wavelength of 666 nm for 60 sec with a total dose of 30 j/cm2. Intravitreal environment parfocality using vitrectomy deleted modified the retina and the products of destruction of tumor tissue and to balance the amount of parfocality additional introduction. Spent restrictive endolaser coagulation section retinotomy. Replaced parfocality on silicone oil. The operation was finished suturing the areas of sclerotome and conjunctiva.

When the control ULTRASOUND after 6 months on the location of the tumors was determined flat seams up to 1 mm thick. Later in the follow-up period of 1.5 years signs of recurrence was not detected. Installed total destruction of intraocular tumors, excluded the remission of tumor cells in the surgical field, reduced the risk of tumour cell dissemination and metastasis.

Example 2. Patient B., 68 years, the village is upil in Kaluga branch of IRTC “eye microsurgery” diagnosis “melanoma of the choroid of the left eye. Localization of tumor - postequalization in the lower outer quadrant. The size of the tumor according to the ULTRASONIC B-scanning: 6 to 8 mm and a height of prominence 3 mm.

At the preparatory stage after processing processing operating margins held anesthetic management. Then had a vitrectomy and filled the vitreal cavity performability. Transscleral diaphanoscopy said localization and dimensions of intraocular tumors. Then 2/3 of the thickness of the sclera above the intraocular neoplasm formed scleral pocket rectangular base from the limbus. Through the formed bed introduced into the structure of intraocular tumors 8 electrodes made of platinum. Spent the electrochemical degradation of intraocular tumors with rated current 100 mA for 1 minute and removed the electrodes. The superficial scleral flap was returned to its place and recorded interrupted sutures. Then intravenously introduced as a photosensitizer 0.1% aqueous solution of chlorine, namely photodithazine, at a dose of 1.1 mg/kg Conducted a visual inspection of fluorescence of cells intraocular tumors using fluorescent diagnostics, and upon reaching the maximum level of saturation of intraocular tumors photosensitizer spent his intraware the aspects of transretinol laser irradiation parallel light beam with a wavelength of 661 nm for 180 sec with a total dose of 30 j/cm 2. Intravitreal environment performability using vitrectomy deleted modified the retina and the products of destruction of tumor tissue. To balance the volume of performability additional introduction. Spent the restrictive endolasercoagulation section retinotomy. Performability replaced by silicone oil. The operation was finished suturing the areas of sclerotome and conjunctiva.

When the control ULTRASOUND after 6 months on the location of the tumors was determined flat seams up to 1 mm thick. Later in the follow-up period of 1.5 years signs of recurrence was not detected. Installed total destruction of intraocular tumors, excluded the remission of tumor cells in the surgical field, reduced the risk of tumour cell dissemination and metastasis.

1. A method of surgical removal of intraocular tumors, including performing a vitrectomy, a surgical removal of intraocular tumors and tamponade with silicone oil, characterized in that after vitrectomy fill vitreal cavity performancesin connection intravitreal, transnationale in intraocular neoplasm introduce two electrodes made of platinum group metal, carried out the electrochemical destr is the Ktsia intraocular tumors with rated current of 10 mA for 10 min or with rated current 100 mA for 1 min when changing the polarity of the electrodes and their location, remove the electrodes, and then intravenously injected as a photosensitizer 0.1 to 1%aqueous solution of chlorine selected from the group Photolon, Radachlorin or photoditazine at a dose of 0.8-1.1 mg/kg, carry out a visual inspection of the fluorescence of the cells of intraocular tumors using fluorescent diagnostics and upon reaching the maximum level of saturation of intraocular tumors photosensitizer spend it intravitreal, transnationale environment performancesthe connection laser irradiation parallel light beam with a wavelength of 661-666 nm at a total dose of irradiation 30-120 j/cm2then using vitrectomy intravitreal remove modified the retina and the products of destruction of tumor tissue-compensated volume performancesthe connection additional introduction, conduct restrictive endolasercoagulation section retinotomy replace performancesee connection with silicone oil, and the surgery is completed by suturing the areas of sclerotome and conjunctiva.

2. The method according to claim 1, characterized in that as performancesthe connection to fill the vitreal cavity using, for example, performancecriteria, performability or parfocality.

3. The method according to claims 1 and 2, characterized in that the quality of the platinum group metals of the electrodes using platinum, iridium or rhodium.

4. A method of surgical removal of intraocular tumors, including performing a vitrectomy, a surgical removal of intraocular tumors and tamponade with silicone oil, characterized in that after vitrectomy vitreal cavity fill performancesin connection transscleral diaphanoscopy precise localization and dimensions of intraocular neoplasms, then 2/3 of the thickness of the sclera above the intraocular neoplasm form a scleral pocket rectangular base from limb, formed through the bed is introduced into the structure of intraocular neoplasms multiple electrodes made of platinum group metal, changing their polarity conducting electrochemical destruction of intraocular tumors with rated current of 10 mA for 10 min or with rated current 100 mA for 1 min and remove the electrodes, the superficial scleral flap returns to its place and fixed with interrupted sutures, is injected as a photosensitizer 0.1 to 1%aqueous solution of chlorine selected from the group Photolon, Radachlorin or photoditazine at a dose of 0.8-1.1 mg/kg, then carry out a visual inspection of the fluorescence of the cells of intraocular tumors using fluorescent diagnostics and upon reaching the maximum UB is nya saturation intraocular tumor photosensitizer spend it intravitreal, transretinol environment performancesthe connection laser irradiation parallel light beam with a wavelength of 661-666 nm with a total dose of 30 to 90 j/cm2then using vitrectomy intravitreal remove modified the retina and the products of destruction of tumor tissue-compensated volume performancesthe connection additional introduction, conduct the restrictive endolasercoagulation section retinotomy replace performancesee connection with silicone oil, and the surgery is completed by suturing the areas of sclerotome and conjunctiva.

5. The method according to claim 4, characterized in that as performancesthe connection to fill the vitreal cavity using, for example, performancecriteria, performability or parfocality.

6. The method according to claims 4 and 5, characterized in that as a platinum group metal electrodes using platinum, iridium or rhodium, the number of electrodes selected 4 - 8.



 

Same patents:

FIELD: medicine.

SUBSTANCE: method involves building tunnel to posterior eyeball pole in inferoexterior and superexterior quadrants. The tunnel is used for implanting flexible polymer magnetolaser implant to the place, the subretinal neovascular membrane is localized. The implant has a permanent magnet shaped as a cut ring and is provided with drug delivery system and a short focus scattering lens of laser radiator connected to light guide. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 5-7 mTesla units intensity. It is arranged with its north pole turned towards sclera at the place of the subretinal neovascular membrane projection with extrascleral arrangement of laser radiator lens membrane being provided in the subretinal neovascular membrane projection area. The other implant end is sutured to sclera 5-6 mm far from the limb via holes made in advance. The implant is covered with conjunctiva and retention sutures are placed thereon. Light guide and drug supply system lead is attached to temple with any known method applied. Drugs are supplied via the implant drug supply system in retrobulbary way in any order. Triombrast is given in the amount of 0,4-0,6 ml and dexamethasone or dexone in the amount of 0,4-0,6 ml during 3-4 days every 12 h. 0.1-1% aqueous solution of khlorin is intravenously introduced at the third-fourth day after setting the implant as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, at a bolus dose of 0.8-1.1 mg/kg. Visual control of subretinal neovascular membrane cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the subretinal neovascular membrane with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at general dose of 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the subretinal neovascular membrane via laser light guide and implant lens, repeated laser irradiation of the subretinal neovascular membrane is carried out with radiation dose of 30-60 J/cm2.

EFFECT: accelerated subretinal edema and hemorrhages resorption; regression and obliteration of the subretinal neovascular membrane; prolonged vision function stabilization.

6 cl

FIELD: medicine.

SUBSTANCE: method involves intravitreously introducing two electrodes into intraocular neoplasm after carrying out vitrectomy and retinotomy to expose the intraocular neoplasm. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with current intensity of 100 mA during 1-10 min or 10 mA during 10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2.The transformed retina and tumor destruction products are intravitreally removed. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. Another embodiment of the invention involves adjusting position and size of the intraocular neoplasm in trans-scleral diaphanoscopic way. Rectangular scleral pocket is built above the intraocular neoplasm to 2/3 of sclera thickness with its base turned away from limb. Several electrodes are introduced into intraocular neoplasm structure via the built bed. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with the same current intensity in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. Superficial scleral flat is returned to its place and fixed with interrupted sutures. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg after having carried out vitrectomy and retinotomy. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2. The transformed retina and tumor destruction products are intravitreally removed using vitreotome. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. The number of electrodes is equal to 4-8.

EFFECT: reduced risk of metastasizing.

4 cl, 13 dwg

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating vascular cutaneous neoplasms, such as nevus flammeus and gemangiomas. Light-thermal impact at energy ranged 39-47 J/sq. cm should be performed in two stages, and between them, 2-3 wk after the onset of vascular resistance at the first stage one should perform beta-therapy daily for 2-3 d at single dosage being 20 g. Then, 3 wk later it is necessary to conduct the second stage of light-thermal impact by starting at energy value being 42 J/sq. cm, not less. The method enables to shorten therapy terms due to applying combined method to affect vascular cutaneous neoplasms.

EFFECT: higher therapeutic and cosmetic effect.

1 ex

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

The invention relates to medicine, namely to Hepatology

The invention relates to medicine, namely to the field of physiotherapy and can be used for treatment of nervous system diseases of the spine
The invention relates to medicine, and is intended for the treatment of pain syndromes in patients with pathology of the peripheral nervous system

FIELD: medicine.

SUBSTANCE: method involves intravitreously introducing two electrodes into intraocular neoplasm after carrying out vitrectomy and retinotomy to expose the intraocular neoplasm. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with current intensity of 100 mA during 1-10 min or 10 mA during 10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2.The transformed retina and tumor destruction products are intravitreally removed. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. Another embodiment of the invention involves adjusting position and size of the intraocular neoplasm in trans-scleral diaphanoscopic way. Rectangular scleral pocket is built above the intraocular neoplasm to 2/3 of sclera thickness with its base turned away from limb. Several electrodes are introduced into intraocular neoplasm structure via the built bed. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with the same current intensity in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. Superficial scleral flat is returned to its place and fixed with interrupted sutures. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg after having carried out vitrectomy and retinotomy. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2. The transformed retina and tumor destruction products are intravitreally removed using vitreotome. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. The number of electrodes is equal to 4-8.

EFFECT: reduced risk of metastasizing.

4 cl, 13 dwg

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

The invention relates to medicine, namely to physiotherapy, and is intended for the rehabilitation of patients in the treatment of fractures of the pelvis

Galvanic comb // 2240840
The invention relates to medicine, namely to prevention devices, and is intended to affect the scalp, stimulation and hair growth

The invention relates to veterinary therapy, namely the treatment of cats in posleoperazionny period

The invention relates to animal husbandry

Dental capsule // 2229860
The invention relates to medicine, specifically to dentistry, and can be used for the treatment of periodontal diseases and diseases of the mucous membranes of the oral cavity, in particular stomatitis
The invention relates to medicine and is intended for diagnostics of muscular
The invention relates to medicine and is intended to perform electrotherapy

FIELD: medicine.

SUBSTANCE: method involves building tunnel to posterior eyeball pole in inferoexterior and superexterior quadrants. The tunnel is used for implanting flexible polymer magnetolaser implant to the place, the subretinal neovascular membrane is localized. The implant has a permanent magnet shaped as a cut ring and is provided with drug delivery system and a short focus scattering lens of laser radiator connected to light guide. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 5-7 mTesla units intensity. It is arranged with its north pole turned towards sclera at the place of the subretinal neovascular membrane projection with extrascleral arrangement of laser radiator lens membrane being provided in the subretinal neovascular membrane projection area. The other implant end is sutured to sclera 5-6 mm far from the limb via holes made in advance. The implant is covered with conjunctiva and retention sutures are placed thereon. Light guide and drug supply system lead is attached to temple with any known method applied. Drugs are supplied via the implant drug supply system in retrobulbary way in any order. Triombrast is given in the amount of 0,4-0,6 ml and dexamethasone or dexone in the amount of 0,4-0,6 ml during 3-4 days every 12 h. 0.1-1% aqueous solution of khlorin is intravenously introduced at the third-fourth day after setting the implant as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, at a bolus dose of 0.8-1.1 mg/kg. Visual control of subretinal neovascular membrane cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the subretinal neovascular membrane with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at general dose of 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the subretinal neovascular membrane via laser light guide and implant lens, repeated laser irradiation of the subretinal neovascular membrane is carried out with radiation dose of 30-60 J/cm2.

EFFECT: accelerated subretinal edema and hemorrhages resorption; regression and obliteration of the subretinal neovascular membrane; prolonged vision function stabilization.

6 cl

Up!